Ambit Biosciences Corporation


We are a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Our pipeline currently includes three programs, each discovered internally and each aimed at the inhibition of validated kinase targets. Our lead drug candidate, quizartinib, is a once-daily, orally administered FMS-like tyrosine kinase 3, or FLT3, kinase inhibitor.

Our Lead Drug Quizartinib

An once-a-day, orally administered, potent and selective FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML).

Learn About Quizartinib» View Recent Presentations»

A Kinase Targeted Pipeline

We leverage our kinase expertise to discover, optimize and develop a sustainable pipeline of small molecule kinase inhibitors.

Learn About Our Pipeline»